Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.59 |
| ▸ | CASR | P41180 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 13/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3348258 | 1.00 | FFAR1 (0.59) | FFAR1FFAR4CASRS1PR1S1PR5 | |
| SCHEMBL7603925 | 0.85 | CASR (0.52) | FFAR1FFAR4CASRS1PR1 | |
| SCHEMBL7603924 | 0.85 | CASR (0.52) | FFAR1FFAR4CASRS1PR1 | |
| SCHEMBL3346797 | 0.84 | FFAR1 (0.43) | FFAR1FFAR4CASRS1PR1S1PR5 | |
| SCHEMBL7604094 | 0.81 | MGLL (0.48) | FFAR1FFAR4CASR | |
| SCHEMBL7604097 | 0.81 | MGLL (0.48) | FFAR1FFAR4CASR | |
| SCHEMBL6374360 | 0.78 | CASR (0.49) | CASRS1PR1S1PR5S1PR3 | |
| SCHEMBL28460083 | 0.78 | FFAR1 (0.57) | FFAR1FFAR4CASRS1PR1S1PR5 | |
| SCHEMBL15435893 | 0.76 | TDP1 (0.56) | FFAR1FFAR4 | |
| SCHEMBL10367487 | 0.76 | TDP1 (0.56) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2141146-A1 | Calcilytic compounds | SmithKline Beecham Corporation (US) | 2010-01-06 | — | — | EP | claimed |
| EP-1254106-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2005-09-14 | — | — | EP | claimed |
| US-20040192741-A1 | Calcilytic compounds | SMITHKLINE BEECHAM CORPORATION & NPS PHARMACEUTICALS | 2004-09-30 | — | — | US | claimed |
| US-20030018203-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2003-01-23 | — | — | US | claimed |
| EP-1254106-A1 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2002-11-06 | — | — | EP | claimed |
| WO-2001053254-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-07-26 | — | — | WO | claimed |
| EP-2141146-A1 | Calcilytic compounds | SmithKline Beecham Corporation (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-1254106-B1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1383511-B1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2006-10-25 | — | — | EP | disclosed |
| US-7109238-B2 | Calcilytic compounds | SMITH KLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1254106-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1383511-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20040192741-A1 | Calcilytic compounds | SMITHKLINE BEECHAM CORPORATION & NPS PHARMACEUTICALS | 2004-09-30 | — | — | US | disclosed |
| EP-1383511-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20040014723-A1 | Calcilytic compounds | SMITHKLINE BEECHAM CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20030018203-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2003-01-23 | — | — | US | disclosed |
| EP-1254106-A1 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2002-11-06 | — | — | EP | disclosed |
| WO-2002034204-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-02 | — | — | WO | disclosed |
| WO-2001053254-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014723-A1 | Calcilytic compounds | SOST, CALCB, CALCR | FFAR1 4113/4885FFAR4 4331/4885CASR 10/4885 |
| US-20030018203-A1 | Calcilytic compounds | SOST, CALCB, CALCR | FFAR1 4113/4885FFAR4 4331/4885CASR 10/4885 |
| US-20040192741-A1 | Calcilytic compounds | SOST, CALCB, CALCR | FFAR1 4113/4885FFAR4 4331/4885CASR 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.